![PE134010: β-GalNAc-PEG3-Azide Pack Size:50 mg 4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2- cyclopenten-1-yl]methyl-β-D-Glucopyranosiduronic Acid](https://cdn.shopify.com/s/files/1/0810/4889/5786/files/PE134010-R_f8bae31b-2c31-46c0-8ea1-611f9226bf78.svg?v=1700577073)
Pay in 4 interest-free payments of $56.25 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2- cyclopenten-1-yl]methyl-β-D-Glucopyranosiduronic Acid
4-Carboxybutyl N-acetyl-β-D-galactosamine
5-(Acetylamino-d3)-2-hydroxybenzoic Acid
C100H159N23O39S / 2339
Myrbetriq-d5
PE134010: β-GalNAc-PEG3-Azide Pack Size:50 mg 4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2- cyclopenten-1-yl]methyl-β-D-Glucopyranosiduronic AcidC14H26N4O9 378. 38 A D N acetylgalactosamine (GalNAc) ligand equipped with an azide handle through a hydrophilic PEG3 spacer. The terminal azide couples to alkynes via copper catalyzed azide alkyne cycloaddition (CuAAC) or to DBCO and related strained alkynes via copper free click chemistry, forming stable 1,2,3 triazole linkages. This compound enables the construction of hepatocyte targeted therapeutics and research tools that exploit the
US$ 406.07
US$ 197.03
US$ 189.62
US$ 211.82
